Essa Pharma Inc EPIX

NAS: EPIX | ISIN: CA29668H7085   16/05/2024
6,250 USD (+0,81%)
(+0,81%)   16/05/2024

14 mei 2024 · ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024 · Persbericht

9 april 2024 · ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference · Persbericht

8 maart 2024 · Essa Pharma Inc. Reports Results Of Annual General Meeting Of Shareholders · Persbericht

13 februari 2024 · ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023 · Persbericht

6 februari 2024 · ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference · Persbericht

25 januari 2024 · ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium · Persbericht

12 december 2023 · ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023 · Persbericht

8 november 2023 · ESSA Pharma to Present at the Jefferies London Healthcare Conference · Persbericht

6 november 2023 · ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement · Persbericht

26 oktober 2023 · ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat · Persbericht

25 oktober 2023 · Thinking about buying stock in Bitfarms, Invo Bioscience, Lucid Group, EngageSmart, or ESSA Pharma? · Persbericht

24 oktober 2023 · Thinking about buying stock in Bitfarms, Invo Bioscience, Lucid Group, EngageSmart, or ESSA Pharma? · Persbericht

21 oktober 2023 · ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the European Society of Medical Oncology 2023 Congress · Persbericht

16 oktober 2023 · Thinking about buying stock in Lithium Americas, AGNC Investment, PCTEL, ESSA Pharma, or Sigma Additive Solutions? · Persbericht

18 september 2023 · ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer · Persbericht

31 augustus 2023 · ESSA Pharma Insiders Establish Automatic Securities Disposition Plans · Persbericht

8 augustus 2023 · ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2023 · Persbericht

6 juni 2023 · ESSA Pharma Appoints Lauren Merendino to its Board of Directors · Persbericht

1 juni 2023 · ESSA Pharma to Present at 2023 Jefferies Healthcare Conference · Persbericht

11 mei 2023 · ESSA Pharma to Present at JMP Securities Life Sciences Conference · Persbericht

Mijn selecties